Epigenetic Strategies to Boost Cancer Immunotherapies-Reference-Cited by-同舟云学术

Epigenetic Strategies to Boost Cancer Immunotherapies

Published:2017-05-23 Issue:6 Volume:18 Page:1108
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Barrero Maria

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Link

http://www.mdpi.com/1422-0067/18/6/1108/pdf

Reference57 articles.

1. Nucleosomal Fluctuations Govern the Transcription Dynamics of RNA Polymerase II

2. The interplay of histone modifications – writers that read

3. DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer;Gnyszka;Anticancer Res.,2013

4. Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success

5. Structure and ligand of a histone acetyltransferase bromodomain

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the epigenetic reader “BET” as a therapeutic strategy for cancer;Bioorganic Chemistry;2023-11

2. Combination of epidrugs with immune checkpoint inhibitors in cancer immunotherapy: From theory to therapy;International Immunopharmacology;2023-07

3. Bromodomain and Extra-Terminal Proteins in Brain Physiology and Pathology: BET-ing on Epigenetic Regulation;Biomedicines;2023-03-01

4. Current understanding of epigenetics role in melanoma treatment and resistance;Cancer Cell International;2022-10-12

5. Epi‐immunotherapy for cancers: rationales of epi‐drugs in combination with immunotherapy and advances in clinical trials;Cancer Communications;2022-06